BiotechTube
AiViva BioPharma

AiViva BioPharma

Los Angeles, United States· Est.
aiviva.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $67M

Overview

AiViva BioPharma is a private, clinical-stage biotech leveraging its proprietary JEL Technology for enhanced drug delivery, primarily in dermatology and ophthalmology. Founded by industry veterans, the company employs a risk-mitigated development strategy to advance a pipeline of novel candidates, with its lead program, AIV001 (axitinib), having completed a Phase 2a study for nonmelanoma skin cancer. AiViva operates as a pre-revenue entity, positioning itself to address significant markets with high unmet need through localized, prolonged-action therapies.

DermatologyOphthalmologyOncologyUrology

Technology Platform

Proprietary JEL Technology designed to prolong therapeutic effects of drugs and enhance benefit-risk profiles, enabling localized, sustained-release formulations (e.g., intradermal injection).

Funding History

4
Total raised:$67M
Series A$25M
Series A$32M
Seed$5M
Seed$5M

Opportunities

The massive, growing incidence of nonmelanoma skin cancer (over 3.6M US cases/year) presents a clear market for a nonsurgical therapy like AIV001.
The proprietary JEL Technology platform offers potential expansion into other high-burden therapeutic areas like ophthalmology, where reducing administration frequency is a major unmet need.

Risk Factors

As a pre-revenue private company, AiViva is dependent on raising capital to fund costly later-stage trials.
Clinical risk remains high, as Phase 2a success does not guarantee later-phase outcomes or regulatory approval.
The competitive landscape in targeted specialty markets is intense, with larger, well-resourced players.

Competitive Landscape

In dermatology, competitors range from other topical/intralesional therapies (e.g., ingenol mebutate, 5-FU) to systemic Hedgehog pathway inhibitors for advanced BCC. In ophthalmology, numerous companies are developing sustained-release technologies for back-of-the-eye diseases. AiViva's differentiation lies in its specific JEL formulation aimed at prolonged local action with potentially improved safety.

More companies in Drug Delivery & Formulation →More companies in United States →